CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-19 | Harris Erik EVP & Chief Commercial Officer | Sale | −295 | $54.78 | $16K | 36,160 |
| 2022-04-19 | Ray Amrit Director | Grant or award | +5,120 | 5,120 | ||
| 2022-04-19 | Ray Amrit Director | Grant or award · Stock Option (Right to Buy) | +9,525 | 9,525 | ||
| 2022-04-16 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | −132 | $84.55 | $11K | 16,914 |
| 2022-03-11 | Kassberg Thomas Richard CBO & EVP | Sale | −10,281 | $67.01 | $689K | 227,559 |
| 2022-03-07 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | −5,140 | $62.95 | $324K | 34,438 |
| 2022-03-04 | Fust Matthew K Director | Option exercise | +7,500 | $40.37 | $303K | 23,195 |
| 2022-03-04 | Fust Matthew K Director | Option exercise · Stock Option (Right to Buy) | −7,500 | 0 | ||
| 2022-03-03 | Dier Mardi CFO & Executive Vice President | Sale | −420 | $64.55 | $27K | 51,808 |
| 2022-03-01 | Dier Mardi CFO & Executive Vice President | Sale | −534 | $66.62 | $36K | 38,228 |
| 2022-03-01 | Dier Mardi CFO & Executive Vice President | Grant or award | +14,000 | 52,228 | ||
| 2022-03-01 | Dier Mardi CFO & Executive Vice President | Grant or award · Stock Option (Right to Buy) | +24,900 | 24,900 | ||
| 2022-03-01 | Harris Erik EVP & Chief Commercial Officer | Sale | −2,713 | $66.62 | $181K | 22,317 |
| 2022-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award | +14,000 | 36,317 | ||
| 2022-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +24,900 | 24,900 | ||
| 2022-03-01 | Pinion John Richard See Remarks | Sale | −4,498 | $66.62 | $300K | 45,266 |
| 2022-03-01 | Pinion John Richard See Remarks | Grant or award | +14,000 | 59,266 | ||
| 2022-03-01 | Pinion John Richard See Remarks | Grant or award · Stock Option (Right to Buy) | +24,900 | 24,900 | ||
| 2022-03-01 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | −843 | $66.62 | $56K | 13,229 |
| 2022-03-01 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Grant or award | +3,710 | 17,046 |
Page 16 of 21 · 410 trades